Business
Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock
–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital– REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the closing of an underwritten public offering of 28,600,000 shares of the Company’s common stock (the “Offering”). The shares of common stock were sold at a public offering price of $1.75 per share, before underwrit
About this update from Hbm Healthcare Investments Ag Temp
[{"type":"image","alt":"Coherus Oncology, Inc.","displaySize":"","headline":null,"caption":"Coherus Oncology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":90,"url":"https://media.zenfs.com/en/globenewswire.com/de46623a0f67971b50edcbf1ccfac170"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Oe14ACN4sd6wayCRQj8VlQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/de46623a0f67971b50edcbf1ccfac170","width":300,"height":90}},"lazy":false},{"type":"text","content":"–The Offering was led by healthcare-dedicated investors including Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital–","length":143,"tagName":"p"},{"type":"text","content":"REDWOOD CITY, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the closing of an underwritten public offering of 28,600,000 shares of the Company’s common stock (the “Offering”). The shares of common stock were sold at a public offering price of $1.75 per share, before underwriting discounts and commissions. All shares in the Offering were sold by the Company. The gross proceeds to Coherus from the Offering were approximately $50.1 million, before deducting underwriting discounts and commissions and other offering expenses. The Company has granted the underwriters of the Offering a 30-day option to purchase up to an additional 4,290,000 shares of common stock at the public offering price, less the underwriting discounts and commissions, solely for the purpose of covering over-allotments.","length":875,"tagName":"p"},{"type":"text","content":"The Offering was led by new investors Janus Henderson Investors, HBM Healthcare Investments and Samsara BioCapital.","length":115,"tagName":"p"},{"type":"text","content":"“Over the last two years we strengthened our balance sheet, reduced our debt by over 80%, and transformed Coherus from a biosimilar company to a clinical-stage Biotech focused on innovative oncology. With this financing we make further progress in rebuilding our capitalization table to support our expanding clinical development programs and upcoming data readouts, while funding commercial efforts to increase market penetration and revenue generation. We believe the Company is well positioned for future success,” said Denny Lanfea...